Overview
Hikma Pharmaceuticals plc has reiterated its full-year 2026 guidance following a first quarter in which all business units performed as expected. Management said performance across core divisions met internal plans and kept its published targets intact.
Injectables division
The Injectables division maintained its guidance for low single-digit percentage revenue growth and a core operating margin range of 27% to 28%. Management reported robust activity across geographies, with particularly strong demand in the United States where Tyzavan, the ready-to-use vancomycin product, contributed materially to sales. Work on expanding capacity at the Bedford facility is progressing as planned, and the Injectables operations in the MENA region and Europe were described as showing positive momentum.
US Rx and contract manufacturing
The US Rx division delivered results in line with expectations. The division's performance was supported by demand for its differentiated branded portfolio and the recent authorized-generic launch of tapentadol in the United States. Separately, Hikma reported continued progress at its Columbus site, which underpins its contract manufacturing organization business.
Strategic portfolio move
Hikma said it has made a strategic decision to exit the 503b compounding business in order to concentrate resources on its core activities. The company framed this as a deliberate refocus rather than an operational retrenchment.
Capital allocation and shareholder returns
As part of its announced buyback program of up to $250 million, Hikma repurchased 4.37 million shares for a total of A354.8 million ( A371.5 million) between February 26 and April 17. The company said these repurchases are progressing under the existing authorization.
Risks and cost environment
Management said it is closely monitoring the evolving geopolitical situation in the Middle East. While demand across that region remains resilient, Hikma noted that inventory levels are currently sufficient to mitigate potential supply chain disruptions. The company also acknowledged some inflationary pressure arising from shipping, energy and insurance costs.
The company reaffirmed its full-year objectives, while continuing to invest in capacity and adjusting its portfolio focus amid external cost pressures and regional geopolitical uncertainty.